Noticias de FBIO_US

Noticias del mercado

Últimas noticias sobre FBIO_US — 89 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: FBIO_US ✕ 89 resultados
30/03/2026 FBIO_US — Bitget
Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
30/03/2026 FBIO_US — Stock Titan
Fortress Biotech (NASDAQ: FBIO) targets $100M+ from Cyprium PRV sale
30/03/2026 FBIO_US — TipRanks
Fortress Biotech Gains Cash From Voucher Sale, Simplifies Capital
30/03/2026 FBIO_US — Stock Titan
Rare-disease voucher sale brings Fortress more than $100M
29/03/2026 FBIO_US — Stock Traders Daily
Why (FBIOP) Price Action Is Critical for Tactical Trading
27/03/2026 FBIO_US — AD HOC NEWS
Fortress Biotech Inc Stock: Business Model, Pipeline Progress, and Investor Considerations in Biotec
26/03/2026 FBIO_US — AD HOC NEWS
Fortress Biotech Inc Stock: Journey Medical's Strong 2025 Results Highlight Growth Potential in Derm
25/03/2026 FBIO_US — GlobeNewswire
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
25/03/2026 FBIO_US — GlobeNewswire
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
20/03/2026 FBIO_US — Stock Titan
Fortress Biotech (FBIO) CEO Lindsay Rosenwald reports 20.7% ownership in 13D/A
20/03/2026 FBIO_US — Minichart
Mustang Bio, Inc. 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, Risks, and Regulatory Overview
18/03/2026 FBIO_US — Stock Traders Daily
Understanding Momentum Shifts in (FBIOP)
28/02/2026 FBIO_US — Intellectia AI
FBIO Should I Buy
24/02/2026 FBIO_US — Stock Traders Daily
Discipline and Rules-Based Execution in FBIOP Response
23/02/2026 FBIO_US — GuruFocus
Fortress Biotech (FBIO) Sells Priority Review Voucher for $205 M
23/02/2026 FBIO_US — Stock Titan
After Menkes drug approval, Fortress moves to cash in $205M voucher
23/02/2026 FBIO_US — GlobeNewswire
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters
23/02/2026 FBIO_US — GlobeNewswire
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
23/02/2026 FBIO_US — StocksToTrade
Fortress Biotech Inc. Faces Stock Volatility Amid Strategic Adjustments​
23/02/2026 FBIO_US — timothysykes.com
Fortress Biotech Inc. Shares Soar After Promising New Developments

Página 4 de 5

keyboard_arrow_up